Replies to post #447853 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Are you really trying to play that losing hand again?

FUDster continues to ignore the Odds Ratios (included in SAP) that clearly showed meaningful IMPROVEMENTS over baseline for both ADAS-Cog and ADCS-ADL. Where >3x of treated patients IMPROVED stat.sig. compared to placebo. Thus, ALL ENDPOINTS MET!

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

• ADCS-Cog and CDR-SB (p < .025) proving further significance of stat. sig. improvements and trial success.

• Identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization) for AA pathway option.

[kevindenver]

The trial was successful, "Missling also stressed this point in his JPM 2024 presentation" "

The trial was successful

LOL, did you feel picked on and felt the need to lash out and support team FUD today?

[Guzzi62]

I have to agree with your statement and I also heard Missling saying just that.

There is no way around it, even for the most hardcore WGT person.

Look at slide 18 in the J.P. Morgan Jan 2024 presentation.


https://jpmorgan.metameetings.net/events/healthcare24/sessions/49893-anavex-life-sciences/webcast?gpu_only=true&kiosk=true